Cleveland BioLabs' Protectan CBLB-502 not selected for defense contract award Jan. 22, 2008 No Comments
Studies examine activity of LY-686017 in alcoholism, social anxiety and IBS Jan. 10, 2008 No Comments
Catalyst reports positive phase II trial results for vigabatrin for cocaine addiction Dec. 11, 2007 No Comments
DOR BioPharma enters cooperative agreement for RiVax with Walter Reed Army Institute Nov. 21, 2007 No Comments
RSS